Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
McKinsey
Medtronic
Boehringer Ingelheim
Merck

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for vibegron

See Plans and Pricing

« Back to Dashboard

Drug Development Status for vibegron: Patents, clinical trial progress, indications

vibegron is an investigational drug.

There have been 9 clinical trials for vibegron. The most recent clinical trial was a Phase 2 trial, which was initiated on June 14th 2018.

The most common disease conditions in clinical trials are Urinary Bladder, Overactive, Prostatic Hyperplasia, and Hyperplasia. The leading clinical trial sponsors are Urovant Sciences GmbH, Merck Sharp & Dohme Corp., and [disabled in preview].

There are five US patents protecting this investigational drug and sixty-three international patents.

Recent Clinical Trials for vibegron
TitleSponsorPhase
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)Urovant Sciences GmbHPhase 3
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)Urovant Sciences GmbHPhase 3
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel SyndromeUrovant Sciences GmbHPhase 2

See all vibegron clinical trials

Clinical Trial Summary for vibegron

Top disease conditions for vibegron
Top clinical trial sponsors for vibegron

See all vibegron clinical trials

US Patents for vibegron

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
vibegron   Start Trial Process for preparing beta 3 agonists and intermediates MERCK SHARP & DOHME CORP. (Rahway, NJ)   Start Trial
vibegron   Start Trial Hydroxymethyl pyrrolidines as .beta.3 adrenergic receptor agonists Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
vibegron   Start Trial Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
vibegron   Start Trial Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for vibegron

Drugname Country Document Number Estimated Expiration Related US Patent
vibegron European Patent Office 2968269 2033-03-15   Start Trial
vibegron European Patent Office 2970927 2033-03-15   Start Trial
vibegron Japan 2016515117 2033-03-15   Start Trial
vibegron Japan 6383403 2033-03-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Medtronic
Boehringer Ingelheim
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.